Please find below all technical applications based on axiom's advanced XFI method:
axiom in vivo small animal application
Status: Offering
Application description:
Deep in vivo tracking based on cusotmer requirements of medical drugs and/or labelled cells, e.g. T-cells in inflammatory bowel disease models.
In vivo cell tracking: axiom insights offers in vivo access to the spatio-temporal distribution of cells for monitoring cell therapies and/or immune reaction. Obtain data at different points in time on the population dynamics of tracked immune cells and visualize this information directly
In vivo medical drugs tracking: axiom insights can assess the efficacy of drugs and drug carrier by studying their pharmacokinetics and in vivo pharmacodynamics when drugs are bound to XFI markers or nanoparticles. This make your biomolecules visible to imaging if it remained invisible so far.
The animal imaging is designed in collaboration with the customer; the induced radiation dose is below damage levels, so the anesthetized test animals will still be alive after the assessment. This allows for the same animals to be used for time series studies and a reduction in the number of test animals required. We have already received the approval from the corresponding Authority for a study on in vivo cell tracking in a Crohn's Disease mouse model. Any new in vivo study needs a new approval.
Advantages:
-
Non-invasive with high spatial and temporal resolution and high sensitivity
-
Several time points over an arbitrarily long diagnostic window period in one single animal unlike ICP-MS. This reduces the number of test animals required.
-
Abritrary depth unlike optical fluorescence
axiom ex vivo (in situ) application
Status: Offering
Application description:
axiom insights provides tracking-data on distribution of molecules of interest in probes like artificial tissues and biological samples for preclinical R&D in pharma nad cosmetic industry.
Advantages:
-
Non-invasive, hence, samples are not damaged
-
Abritrary tissue depth in contrast to laser ablation or optical fluorescence
-
High spatial resolution in contrast to Inductively Coupled Plasma – Mass Spectroscopy (ICP-MS)
axiom assays screening application
Status: Offering
Application description:
axiom insights can measure the uptake of medical drugs/ligands into cells with a very small number of cells to be used, hence lowering the pre-assay preparation work. So, axiom offers a high throughput technique, allowing the uptake of medical drugs into cells to be screened, thereby using much fewer cells than in inductively coupled plasma mass spectrometry (ICP-MS) analytics.
Advantages:
-
High throughput screening (1min per vial)
-
Low number of cells used (about 100 cells with axiom insights vs. approximately 500,000 cells with ICP-MS)
-
Uptake visible down to 0.2 picograms mass of antibody-functionalized Gold-Nano-Particles (GNP) per tumor cell
axiom feasibility & design study
Status: Offering
Application description:
We offer a simulation in order to predict the expected sensitivity and to design the optimal test setup, thereby supporting the final decision-making process
Advantages:
-
Fast feasibility check prior to beginning the major challenge of in vivo research
-
Possibility to adjust settings for improved tracking sensitivity
-
Upfront confidence with axiom insights method
axiom in vitro application
Status: Offering
Application description:
analytics of e.g. uptake of nanoparticles into cells (example: uptake of nanoparticles functionalized with antibodies by prostate tumor cells)
Advantages:
-
Non-invasive, hence, samples are not damaged
-
Abritrary tissue depth in contrast to laser ablation or optical fluorescence
-
High spatial resolution in contrast to Inductively Coupled Plasma – Mass Spectroscopy (ICP-MS)
axiom in vivo human application
Status: R&D phase / work in progress
Application description:
in vivo tracking of medical drugs and/or labelled cells inside human patient is planned as next upgrade of axiom´s portfolio.
R&D is ongoing.